ArticleJournal of the American Heart Association2021
Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis.ESC heart failure · 2024Pooled it
- Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study.PloS one · 2026Trial
- Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy.Heart rhythm O2 · 2026Article
- Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Transthyretin Amyloid Cardiomyopathy: A Propensity-Matched Cohort Study.International journal of heart failure · 2026Article
- Cardiorenal Biomarkers and their Implications in Prognosis and Treatment Response of Transthyretin Cardiac Amyloidosis.Current heart failure reports · 2026Review
- Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.Genes · 2026Review
- Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study.ESC heart failure · 2026Article
- [Terapias dirigidas en amiloidosis cardíaca por transtiretina: una revisión del contexto clínico contemporáneo].Archivos de cardiologia de Mexico · 2025Review
- Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report.European heart journal. Case reports · 2025Article
- The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy.Current cardiology reports · 2025Review
- Trends in Conventional Heart Failure Therapy in a Real-World Multinational ATTR-CA Cohort.Journal of cardiovascular development and disease · 2025Article
- Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift.Cardiac failure review · 2025Review
- Effect of Timely Availability of TTR-Stabilizing Therapy on Diagnosis, Therapy, and Clinical Outcomes in ATTR-CM.Journal of clinical medicine · 2024Article
- Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety.European journal of heart failure · 2024Article
- Review
- A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.Mini reviews in medicinal chemistry · 2024Review
- Changes in Left Ventricular Ejection Fraction and Clinical Trajectories of Transthyretin Cardiac Amyloidosis with Systolic Dysfunction.Journal of clinical medicine · 2023Article
- Conventional heart failure therapy in cardiac ATTR amyloidosis.European heart journal · 2023Article
- SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.ESC heart failure · 2023Article
- Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials.Frontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Background Despite the belief that heart failure therapies are not effective in transthyretin cardiac amyloidosis, data are limited. We tested the association of neurohormonal blockade use with survival. Methods and Results A total of 309 consecutive patients with transthyretin cardiac amyloidosis were identified. Medication inventory was obtained at baseline and subsequent visits. Exposure included a neurohormonal blockade class (β-blocker [βB], angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and mineralocorticoid antagonist) at baseline and subsequent visits. βB was modeled as baseline use, time-varying use, and in an inverse probability treatment weighted model. Primary outcome was all-cause mortality analyzed with adjusted Cox proportional hazards models. Continuing compared with stopping βB during follow-up was tested. Mean age was 73.2 years, 84.1% were men, and 17.2% had atrial fibrillation/flutter at baseline. At the time of study entry, 49.8% were on βBs, 35.0% were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and 23.9% were on mineralocorticoid antagonists. For the total cohort, there was a trend toward harm in the unadjusted model for baseline βB use, but this was neutral after adjustment. When βB use was analyzed as a time-varying exposure, there was no association with mortality. βB discontinuation was associated with decreased mortality for the total cohort. Findings were consistent in inverse probability treatment weighted models. For angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or mineralocorticoid antagonist use, there was no association with mortality after adjustment for the total cohort. Conclusions There was no association of neurohormonal blockade use with survival in transthyretin cardiac amyloidosis. For the total cohort, deprescribing βB may be associated with improved survival. Additional studies are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.